abstract_id,session_title,abstract_title,ground_truth,default_model_primary_drugs,default_model_secondary_drugs,default_model_comparator_drugs,default_model_reasoning,default_model_success,default_model_llm_calls
6022,,"A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma",,"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone"", ""Orelabrutinib"", ""Chidamide"", ""Venetoclax"", ""Lenalidomide"", ""Penpulimab""]",[],"[""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone"", ""Orelabrutinib"", ""Chidamide"", ""Venetoclax"", ""Lenalidomide"", ""Penpulimab"", ""Polatuzumab Vedotin""]","[""1. Read the title and identified explicit drug names and regimen components: Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Orelabrutinib, Chidamide, Venetoclax, Lenalidomide, Penpulimab."", ""2. Recognized 'Pola-RCHP-X' and 'RCHOP-X' and 'Pola-Rchp' as regimen codes; expanded their components using the explicitly listed drugs rather than keeping regimen abbreviations, per rules favoring full names."", ""3. Parsed the phrase 'Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X)' as the primary experimental treatment arm; classified all named drugs in this combination as Primary."", ""4. Interpreted 'Versus RCHOP-X and Pola-Rchp' as comparator arms: RCHOP-X contains Rituximab, Cyclophosphamide, Doxorubicin, Prednisone plus the same X-drugs (Orelabrutinib, Chidamide, Venetoclax, Lenalidomide, Penpulimab), while Pola-Rchp represents Polatuzumab Vedotin plus RCHP; therefore, the same component drugs act as comparators in those arms."", ""5. Assigned the overlapping drugs that appear within RCHOP-X and Pola-Rchp as Comparator Drugs as well, because they are parts of the regimens on the 'versus' side of the comparison."", ""6. Found no 'with or without', '\u00b1', or 'and/or' constructions indicating optional secondary drugs; thus left Secondary Drugs empty."", ""7. Excluded regimen abbreviations themselves (Pola-RCHP-X, RCHOP-X, Pola-Rchp) from output, following the rule to prefer expanded component drugs when available."", ""8. Applied formatting rules: singular drug names, title casing preserved, components separated by ';;' conceptually (as array elements in JSON).""]",True,1
148,,Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial,,"[""BrECADD"", ""Ebeacopp""]",[],[],"[""1. Read the abstract title to identify all drug-like or regimen-like terms used for treatment."", ""2. Detected BrECADD and eBEACOPP as named chemotherapy regimens administered in the HD21 trial."", ""3. No individual component drugs were provided for these regimens, so per rules the regimen names themselves are captured."", ""4. Both regimens are treatments under study rather than comparator terms explicitly marked with 'vs' or 'compared with', so they are classified as Primary."", ""5. Normalized capitalization for eBEACOPP to Ebeacopp while keeping BrECADD as written, and produced the final JSON with no Secondary or Comparator drugs.""]",True,1
671,,Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma:a Phase 2 Multicenter Study,,"[""Rituximab"", ""Ifosfamide"", ""Mesna"", ""Mitoxantrone"", ""Etoposide""]",[],[],"[""1. Parsed the title and identified 'R-MINE (RMINE+X)' as a regimen name in a combination therapy context."", ""2. Recognized R-MINE as a standard regimen consisting of Rituximab, Ifosfamide, Mesna, Mitoxantrone, and Etoposide based on common oncology usage."", ""3. Applied the rule to expand regimen abbreviations into individual drug components when the full regimen expansion is known."", ""4. Treated the RMINE-based regimen as the active treatment arm, thus classifying its constituent drugs as Primary."", ""5. The 'Novel Targeted Agents' and 'X' are unspecified and thus not extractable as specific drugs; no explicit comparator arm or optional ('with or without', '\u00b1') drug was mentioned, so Secondary and Comparator lists remain empty."", ""6. Formatted the final output according to naming, singularization, and separator conventions.""]",True,1
4792,,"A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics",,"[""Glofitamab"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisolone"", ""Polatuzumab Vedotin""]",[],[],"[""1. Parsed the title and identified drug/regimen-like strings: Glofitamab-R-CHOP, Glofitamab-Polatuzumab Vedotin-R-CHP, FDG-PET."", ""2. Recognized R-CHOP and R-CHP as chemotherapy regimens and expanded them to constituent drugs where standard: Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone (vincristine is typically included in CHOP but not clearly specified here and thus not added)."", ""3. Applied inclusion rules to capture specific drugs and regimens used for treatment: Glofitamab, Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone, Polatuzumab Vedotin."", ""4. Excluded FDG-PET because it is mentioned in the context of imaging/response characteristics (diagnostic modality) rather than as a therapeutic agent."", ""5. Classified all identified treatment drugs as Primary since they are components of the experimental regimens being evaluated; no 'with or without' or '\u00b1' constructs to define Secondary drugs, and no 'vs/versus/compared to' constructs indicating Comparator drugs."", ""6. Assembled and formatted the final lists per required JSON structure and formatting rules.""]",True,1
2723,,Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel,,"[""Idecabtagene Vicleucel"", ""Ciltacabtagene Autoleucel""]",[],[],"[""1. Read the title and identified capitalized multi-word phrases that match known drug names: Idecabtagene Vicleucel and Ciltacabtagene Autoleucel."", ""2. Confirmed both as CAR-T cell products used therapeutically for multiple myeloma, thus included under the drug-extraction rules."", ""3. Detected the phrase 'treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel', where 'or' indicates both are main treatment options rather than optional add-ons or controls."", ""4. Classified both Idecabtagene Vicleucel and Ciltacabtagene Autoleucel as Primary Drugs and found no 'with or without', '\u00b1', or 'vs/compared with' patterns to justify Secondary or Comparator classifications."", ""5. Applied formatting rules (title casing, use of ';;' only between multiple entries) and produced the final JSON.""]",True,1
2983,,The Effects of Tranexamic Acid and Recombinant Activated Factor VII on Traumatic Bleeding and Mortality in Mice,,"[""Tranexamic Acid"", ""Recombinant Activated Factor VII""]",[],[],"[""1. Read the abstract title and identified drug-like phrases."", ""2. Detected 'Tranexamic Acid' and 'Recombinant Activated Factor VII' as specific administered agents."", ""3. Noted they are connected by 'and', which per guidelines indicates co-primary therapies."", ""4. Found no 'with or without', '\u00b1', or 'vs/versus/compared' constructs, so no secondary or comparator drugs are implied."", ""5. Applied inclusion and formatting rules to list both agents as Primary Drugs and left other categories empty.""]",True,1
3344,,Real World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,,"[""Axicabtagene Ciloleucel"", ""Lisocabtagene Maraleucel""]",[],"[""Lisocabtagene Maraleucel""]","[""1. Read the title and identified capitalized, drug-like multi-word phrases as candidates."", ""2. Extracted candidate drugs: Axicabtagene Ciloleucel and Lisocabtagene Maraleucel, both known CAR-T cell products used therapeutically."", ""3. Noted the comparative structure 'Comparison of X and Y', which per guidelines implies a comparison between two active treatments."", ""4. Classified both Axicabtagene Ciloleucel and Lisocabtagene Maraleucel as Primary because they are the main therapeutic agents under study."", ""5. Applied comparator rule (comparing A and B \u2192 B as Comparator) and labeled Lisocabtagene Maraleucel as Comparator as well."", ""6. Confirmed there were no 'with or without' or '\u00b1' structures, so no Secondary drugs were assigned."", ""7. Verified no broad therapy-class terms or non-therapeutic items needed to be excluded and formatted final JSON.""]",True,1
3677,,Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide,,"[""Belantamab Mafodotin"", ""Pomalidomide"", ""Dexamethasone""]",[],"[""Pomalidomide"", ""Bortezomib"", ""Dexamethasone"", ""Lenalidomide""]","[""1. Parsed the title and identified all specific drug names: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib, Lenalidomide."", ""2. Detected the structure 'Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone', where 'plus' and 'and' indicate co-administered primary regimen components."", ""3. Classified Belantamab Mafodotin, Pomalidomide, and Dexamethasone in the first arm as Primary Drugs because they form the main treatment regimen under study."", ""4. Used the keyword 'Vs' (versus) to identify the second regimen 'Pomalidomide Plus Bortezomib and Dexamethasone' as the comparator, classifying Pomalidomide, Bortezomib, and Dexamethasone as Comparator Drugs."", ""5. Noted that Lenalidomide appears in the phrase 'received 1 prior line of therapy including Lenalidomide'; while generally prior therapies are excluded, it is mentioned in a comparative/eligibility context, so it was conservatively classified as a Comparator Drug per instructions to favor comparator classification when in doubt."", ""6. Verified there were no 'with or without' or '+/-' constructs, so no Secondary Drugs were assigned, and ensured output formatting (casing, separators) matches the specified rules.""]",True,1
564,,"Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) Results in Higher Remission Rates over Conventional 7+3 Chemotherapy without Increased Toxicity in Newly Diagnosed Acute Myeloid Leukemia",,"[""Venetoclax"", ""Cladribine"", ""Idarubicin"", ""Cytarabine""]",[],[],"[""1. Parsed the title and identified drug-like terms: Venetoclax, Cladribine, Idarubicin, Cytarabine, and the regimen code CLIA plus the phrase '7+3 chemotherapy'."", ""2. Mapped CLIA to its component drugs already listed (Cladribine, Idarubicin, Cytarabine) and therefore did not capture CLIA separately per regimen rules."", ""3. Recognized 'Venetoclax Combined with Cladribine, Idarubicin, Cytarabine' as the treatment being evaluated; 'combined with' indicates all four are co-primary agents."", ""4. Interpreted 'over Conventional 7+3 Chemotherapy' as a comparator description but without explicit drug names, and excluded it as a broad therapy term per exclusion rules."", ""5. Classified Venetoclax, Cladribine, Idarubicin, and Cytarabine as Primary Drugs; no Secondary or Comparator drugs were identified.""]",True,1
876,,Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs,,"[""CAR-T Cell""]",[],[],"[""1. Parsed the title and identified therapy-related biological agents and cell therapies: Tandem CAR-T-Cell Therapy, CD5, CD7, Epitope-Edited Allogeneic HSCs."", ""2. Applied inclusion rules for cell therapies, which state that CAR-T therapies should be captured as 'CAR-T Cell' and that stem cell transplantations map to specific 'Cell' terms only when clearly used as treatment for the disease."", ""3. Determined that 'Tandem CAR-T-Cell Therapy targeting CD5 and CD7' represents the therapeutic intervention; targets CD5 and CD7 are antigens, not drugs, so they were not captured as separate drugs."", ""4. Interpreted 'Epitope-Edited Allogeneic HSCs' (hematopoietic stem cells) as engraftment/conditioning context rather than the primary therapeutic drug for disease treatment in the title, so did not capture it as a separate cell therapy drug."", ""5. Classified 'CAR-T Cell' as a Primary Drug per the CAR-T inclusion rules and recorded no Secondary or Comparator drugs."", ""6. Normalized the CAR-T term to 'CAR-T Cell' per formatting requirements and produced the final JSON.""]",True,1
4835,,"Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL",,"[""CD19/CD22-CAR T Cell"", ""Allogeneic Hematopoietic Cell""]",[],[],"[""1. Read the title and identified therapy-related phrases: 'CD19/CD22-CAR T Cells' and 'Allo-HCT'."", ""2. Recognized 'CD19/CD22-CAR T Cells' as a specific CAR-T cell therapy and normalized it to singular 'CD19/CD22-CAR T Cell' per cell therapy rules."", ""3. Interpreted 'Allo-HCT' as allogeneic hematopoietic cell transplantation and normalized it to 'Allogeneic Hematopoietic Cell' according to the stem cell therapy mapping rules."", ""4. Detected the connector 'with' indicating both therapies are co-administered as part of the main regimen, thus classifying both as Primary."", ""5. Found no 'with or without', '\u00b1', or 'and/or' patterns to define Secondary drugs and no 'vs', 'versus', or 'compared with' patterns to define Comparator drugs."", ""6. Applied formatting rules (singular forms, capitalization, separators) and produced the final JSON.""]",True,1
3429,,"ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs",,"[""Asciminib""]",[],[],"[""1. Read the abstract title and identified pharmacologic terms and study names."", ""2. Detected 'Asciminib' as a specific drug; 'Ascembl Study' is a trial name, and 'TKIs' is a drug class, both excluded per rules."", ""3. Noted that the comparison is between RCT and real-world evidence, not between different drugs, so no explicit comparator drug is specified."", ""4. Classified Asciminib as a Primary Drug because it is the therapeutic agent under evaluation."", ""5. Confirmed no 'with or without' or '\u00b1' constructs (so no Secondary Drug) and no 'vs/compared with' tied to a specific alternative drug (so no Comparator Drug)."", ""6. Assembled the final JSON with Asciminib as the sole Primary Drug and empty arrays for Secondary and Comparator Drugs.""]",True,1
3489,,Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up,,"[""Ibrutinib""]",[],[],"[""1. Read the abstract title and identified candidate therapeutic terms."", ""2. Detected 'Ibrutinib' as a specific named drug used for first-line treatment."", ""3. Found no phrases indicating optional add-on therapy (with or without, \u00b1) that would define any Secondary drugs."", ""4. Found no explicit comparator terms (vs, versus, compared with) naming another drug or regimen, so no Comparator drugs were identified."", ""5. Classified Ibrutinib as a Primary drug because it is the main treatment being evaluated."", ""6. Applied formatting rules (singular form, title casing, no extra spaces) and produced the final JSON.""]",True,1
4343,,Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia,,"[""Revumenib""]",[],[],"[""1. Read the abstract title to identify any named therapeutic agents or regimens."", ""2. Detected 'Revumenib' as the only specific drug mentioned in the context of treatment for relapsed or refractory KMT2Ar acute leukemia."", ""3. No phrases indicating optional add-on therapy (with or without, \u00b1, and/or) were present, so no Secondary drugs were identified."", ""4. No comparison terms such as 'vs', 'versus', 'compared with', or 'compared to' were present, so no Comparator drugs were identified."", ""5. Classified Revumenib as a Primary drug because it is the main therapy being studied in the Phase 2 trial."", ""6. Constructed the final JSON with Revumenib as Primary and empty arrays for Secondary and Comparator drugs.""]",True,1
4356,,Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia,,"[""Enzomenib""]",[],[],"[""1. Parsed the title to identify candidate therapeutic agents mentioned for treatment of relapsed or refractory acute leukemia."", ""2. Detected 'Enzomenib (DSP-5336)' as a specific drug; 'Menin-MLL inhibitor' is a mechanism/class description, not a drug name, and was excluded."", ""3. No combination indicators (with, plus, versus, compared to, with or without) were present, so only Enzomenib is considered."", ""4. Classified Enzomenib as the Primary drug since it is the focus of this first-in-human Phase 1/2 study."", ""5. Confirmed there are no secondary or comparator agents mentioned and formatted the final JSON output accordingly.""]",True,1
4460,,Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study,,"[""Rituximab""]",[],[],"[""1. Read the abstract title and identified candidate therapeutic terms: 'Watchful Waiting' and 'Rituximab'."", ""2. Determined that 'Watchful Waiting' is a management strategy, not an administered drug, so it was excluded per non-therapeutic item rules."", ""3. Recognized 'Rituximab' as an anticancer drug used as first-line treatment in the study."", ""4. The phrase 'Vs.' indicates a comparison between watchful waiting and Rituximab, but only Rituximab is a drug, so it is treated as the main therapeutic agent rather than a comparator drug name."", ""5. Classified Rituximab as a Primary Drug and left Secondary and Comparator lists empty."", ""6. Applied formatting rules (title casing, singular form, no extra spaces) and produced the final JSON.""]",True,1
4461,,"Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from ""FOLL12"" Phase III Trial of the Fondazione Italiana Linfomi",,"[""Rituximab""]",[],[],"[""1. Read the abstract title and identified drug-like terms and therapy-related phrases."", ""2. Detected 'Rituximab' as a specific monoclonal antibody drug; no other specific drugs or regimens are named."", ""3. Recognized 'Rituximab' as being used in a maintenance treatment context, so it is included as a therapeutic agent."", ""4. Found no 'with or without', '\u00b1', or 'and/or' constructs indicating secondary drugs, and no 'vs', 'versus', or 'compared' constructs indicating comparator drugs."", ""5. Classified Rituximab as a Primary Drug and left Secondary and Comparator arrays empty, then formatted the final JSON.""]",True,1
4617,,"ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia",,"[""Mitapivat""]",[],[],"[""1. Read the abstract title and identified drug-like terms and comparators."", ""2. Detected 'Mitapivat' as a specific named drug under investigation."", ""3. Noted 'placebo' as a comparator but excluded it per the explicit rule to always exclude placebo."", ""4. Confirmed no combination phrases such as 'with or without' or '\u00b1' indicating secondary drugs."", ""5. Classified Mitapivat as Primary because it is the main therapeutic agent studied in this trial."", ""6. Produced final JSON with Mitapivat as Primary and no Secondary or Comparator drugs.""]",True,1
4724,,Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial,,"[""Lacutamab""]",[],[],"[""1. Read the abstract title and identified therapy-related terms."", ""2. Detected 'Lacutamab' as the only specific named therapeutic agent."", ""3. Confirmed Lacutamab is being administered as treatment ('treated by Lacutamab'), so classified it as a Primary drug."", ""4. Found no phrases indicating optional add-on therapy (with or without, \u00b1, and/or), so no Secondary drugs."", ""5. Found no comparator indicators (vs, versus, compared to), so no Comparator drugs."", ""6. Applied formatting rules (title case, single name, no extra spaces) and produced the final JSON.""]",True,1
4751,,"Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)",,"[""Divesiran""]",[],[],"[""1. Read the abstract title and identified drug-like terms and descriptors."", ""2. Detected 'Divesiran' as a named investigational siRNA therapeutic agent; 'Galnac conjugated siRNA' is a mechanism/format, not a separate drug name."", ""3. No phrases such as 'with or without', 'plus/minus', 'versus', or 'compared to' indicating secondary or comparator drugs were present."", ""4. Classified Divesiran as a Primary Drug because it is the main therapeutic agent being evaluated in this Phase 1/2 study."", ""5. Excluded non-drug terms and mechanisms per rules and formatted the final lists.""]",True,1
4866,,A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3,,"[""Ianalumab""]",[],[],"[""1. Read the abstract title and identified therapy-related terms."", ""2. Detected 'Ianalumab' as the only specific drug name mentioned."", ""3. Noted that 'previously treated with at least two lines of therapy' refers to prior, unspecified treatments, which are excluded per rules."", ""4. Classified Ianalumab as a Primary drug because it is the main agent being studied in this Phase 2 trial."", ""5. Found no 'with or without', '\u00b1', 'and/or', or similar constructions indicating Secondary drugs."", ""6. Found no 'vs', 'versus', 'compared with', or similar comparator language, so no Comparator drugs were identified."", ""7. Applied formatting rules (singular form, title casing, no extraneous terms) and produced the final JSON.""]",True,1
5173,,"HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30+ T Cell Lymphoma: Clinical Results of a Phase I/II Trial",,"[""HSP-CAR30"", ""CART30""]",[],[],"[""1. Read the abstract title and identified therapeutic entities under investigation."", ""2. Detected 'HSP-CAR30' and 'CART30' as specific CAR-T\u2013type cell therapies being administered for treatment."", ""3. Applied inclusion rules for cell therapies, capturing the named constructs exactly as written in the title."", ""4. Found no phrases indicating optional co-therapy (with or without, \u00b1) so no Secondary drugs were identified."", ""5. Found no comparator indicators (vs, versus, compared with/to), so no Comparator drugs were identified."", ""6. Classified HSP-CAR30 and CART30 as Primary since they are the main therapeutic agents in this Phase I/II trial."", ""7. Verified that no broad therapy classes or non-therapeutic terms were incorrectly included.""]",True,1
5613,,Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results,,"[""Iptacopan""]",[],[],"[""1. Read the title to identify any named drugs or therapeutic agents."", ""2. Detected 'Iptacopan' as a specific drug and 'Monotherapy' as a general therapy term."", ""3. Excluded 'Monotherapy' because it is a broad therapy-class term, not a drug name."", ""4. Classified Iptacopan as a Primary drug since it is the sole treatment under study."", ""5. Found no 'with or without', '\u00b1', 'and/or', or similar patterns indicating Secondary drugs."", ""6. Found no 'vs', 'versus', 'compared with', or similar comparator language, so no Comparator drugs."", ""7. Assembled the final JSON with Iptacopan as the only Primary drug and empty arrays for Secondary and Comparator.""]",True,1
66,,"Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6",,"[""DISC-3405""]",[],[],"[""1. Read the title: 'Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6'."", ""2. Identified candidate therapeutic entities: DISC-3405 and TMPRSS6."", ""3. Recognized DISC-3405 as the investigational recombinant humanized antibody (drug being studied)."", ""4. Recognized TMPRSS6 as a biological target, not an administered therapeutic agent, so excluded it per exclusion rules."", ""5. No 'with or without', 'plus/minus', or 'versus/compared to' patterns detected, so only a single primary drug is present and no secondary or comparator drugs."", ""6. Classified DISC-3405 as Primary and formatted the final JSON.""]",True,1
3323,,"Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials",,"[""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisolone"", ""Anti-CD20""]",[],[],"[""1. Parsed the title and identified 'Mini-CHOP' and 'Anti-CD20' as therapy-related terms in the treatment context."", ""2. Recognized Mini-CHOP as an attenuated form of the CHOP regimen consisting of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone."", ""3. Applied the rule to expand regimen abbreviations into individual drugs when full component names are known, excluding the regimen acronym itself."", ""4. Interpreted 'Mini-CHOP Plus Anti-CD20' with 'plus' indicating co-administered primary therapies."", ""5. Classified Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, and Anti-CD20 as Primary Drugs and found no 'with or without' or 'versus' patterns indicating secondary or comparator drugs."", ""6. Verified that no other broad therapy terms (e.g., 'chemotherapy') or non-drug terms should be included.""]",True,1
2640,,Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study,,"[""Rituximab"", ""Gemcitabine"", ""Oxaliplatin""]",[],[],"[""1. Read the abstract title and identified 'R-GemOx' as a named chemotherapy regimen used to treat diffuse large B-cell lymphoma."", ""2. Recognized that R-GemOx is a standard abbreviation for the combination of Rituximab, Gemcitabine, and Oxaliplatin."", ""3. Applied the rule to expand identifiable regimen components into individual drug names instead of keeping the regimen abbreviation."", ""4. Classified Rituximab, Gemcitabine, and Oxaliplatin as Primary drugs because they constitute the treatment under study."", ""5. Found no 'with or without', '\u00b1', 'and/or', or comparator terms like 'vs' or 'compared with', so no Secondary or Comparator drugs were assigned."", ""6. Ensured proper title casing and formatting with ';;' separators in the final lists.""]",True,1
1356,,Split-Dose R-CHOP for Older Patients with Treatment Naive DLBCL,,"[""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisolone""]",[],[],"[""1. Read the title: 'Split-Dose R-CHOP for Older Patients with Treatment Naive DLBCL'."", ""2. Recognized R-CHOP as a standard chemotherapy regimen used therapeutically for DLBCL."", ""3. Applied inclusion rule for regimens: expand R-CHOP into its component drugs (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) and exclude the regimen code itself."", ""4. There is no 'with or without', '\u00b1', or 'and/or' structure indicating secondary drugs, and no 'vs', 'versus', or 'compared with' indicating comparator drugs."", ""5. Classified all component drugs of R-CHOP as Primary because they form the main treatment regimen under study."", ""6. Verified formatting: singular drug names, title casing, separated by ';;' only in arrays if multiple entries.""]",True,1
1208,,Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy,,"[""CAR-T Cell""]",[],[],"[""1. Read the title: 'Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy'."", ""2. Identified 'CAR-T Therapy' as involving CAR-T cell treatment, which qualifies as a cell-based therapeutic agent."", ""3. Normalized this to the standardized form 'CAR-T Cell' per inclusion rules for CAR-T therapies."", ""4. Found no explicit co-administered drugs or comparator agents; 'management' is general and not a specific drug."", ""5. Classified 'CAR-T Cell' as a Primary drug since it is the main therapeutic modality referenced."", ""6. Left Secondary and Comparator drug lists empty and formatted the final JSON.""]",True,1
3863,,Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies,,"[""IL-18""]",[],[],"[""1. Parsed the title: 'Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies'."", ""2. Identified 'IL-18' as an interleukin cytokine administered as a therapeutic agent; 'decoy-resistant' is a modifier, not a separate drug."", ""3. No combination markers (plus, with, and, vs, compared to, with or without) indicating additional or comparator drugs were present."", ""4. Classified IL-18 as the sole Primary drug under investigation."", ""5. Confirmed there are no Secondary or Comparator drugs and formatted the final JSON output.""]",True,1
2663,,Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma,,"[""18FDG""]",[],[],"[""1. Parsed the abstract title to identify any drug or diagnostic agent names."", ""2. Detected '18FDG' within '18FDG PET/CT' as a radiotracer used diagnostically."", ""3. Applied inclusion rules that allow diagnostic agents like 18FDG to be captured."", ""4. Found no combination phrases (plus, with, versus, etc.) indicating secondary or comparator roles."", ""5. Classified 18FDG as a Primary agent in this diagnostic context and left Secondary and Comparator lists empty.""]",True,1
686,,"The Effectiveness of Levofloxacin in Prevention of Febrile Episodes in Non-Hodgkin Lymphoma Patients Receiving Rituximab, Cyclophosphamide, Vincristine, Doxorubicin and Prednisolone (R-CHOP)",,"[""Levofloxacin"", ""Rituximab"", ""Cyclophosphamide"", ""Vincristine"", ""Doxorubicin"", ""Prednisolone""]",[],[],"[""1. Parsed the title and identified drug-like terms: Levofloxacin, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone, and regimen code R-CHOP."", ""2. Recognized R-CHOP as a regimen containing the already-listed specific drugs, and per rules excluded the abbreviated regimen name in favor of the expanded component drugs."", ""3. Determined that Levofloxacin is the main agent being evaluated for prevention of febrile episodes, thus classified as Primary."", ""4. Noted that Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, and Prednisolone are concurrently administered therapeutic drugs (background chemotherapy regimen) and therefore included as co-primary treatments."", ""5. Found no 'with or without', '\u00b1', or 'and/or' constructs indicating secondary drugs and no 'vs', 'versus', or 'compared to' constructs indicating comparator drugs."", ""6. Applied formatting rules (singular names, title casing, ';;' as internal separator only) and produced the final JSON.""]",True,1
661,,"Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study",,"[""Mitoxantrone Hydrochloride Liposome"", ""Gemcitabine"", ""Cisplatin"", ""Dexamethasone""]",[],[],"[""1. Read the title and identified capitalized, drug-like terms."", ""2. Extracted candidate therapies: Mitoxantrone Hydrochloride Liposome, Gemcitabine, Cisplatin, Dexamethasone."", ""3. Noted the phrase 'Combination of ... with ...' indicating all listed agents are co-administered as part of the treatment regimen, so all are Primary."", ""4. Confirmed there is no 'with or without', '\u00b1', or 'and/or' structure to indicate Secondary drugs, and no 'vs', 'versus', or 'compared with' to indicate Comparator drugs."", ""5. Applied formatting rules (title casing preserved, separated by ';;') and produced the final categorized lists.""]",True,1
2339,,"Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP+-R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis",,"[""Cyclophosphamide"", ""Mitoxantrone Hydrochloride Liposome"", ""Vincristine"", ""Prednisone""]","[""Rituximab""]",[],"[""1. Read the title and identified all specific drug or regimen names mentioned."", ""2. Extracted candidate drugs: Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, Prednisone, Rituximab, and the regimen abbreviation CMOP+-R."", ""3. Applied the rule to exclude regimen abbreviations when full component drugs are provided, so excluded CMOP+-R."", ""4. Noted the phrase 'Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab', where the core regimen drugs are always given and Rituximab may be added."", ""5. Used the 'with or without' pattern to classify the consistently present regimen drugs (Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, Prednisone) as Primary and the optional drug (Rituximab) as Secondary."", ""6. Confirmed that no explicit 'vs', 'versus', 'compared with/to' statements specify a distinct comparator drug regimen, so left Comparator Drugs empty."", ""7. Formatted the final lists per casing and separator rules and returned the JSON.""]",True,1
335,,"Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia",,"[""Hyper-CVAD"", ""Inotuzumab Ozogamicin"", ""Blinatumomab""]","[""Inotuzumab Ozogamicin""]",[],"[""1. Read the title and identified drug-like terms: Hyper-CVAD, Inotuzumab Ozogamicin, Blinatumomab."", ""2. Retained Hyper-CVAD as a regimen name because no expanded component drug list is provided in the title."", ""3. Detected the phrase 'with or without Inotuzumab Ozogamicin', which per rules makes Inotuzumab Ozogamicin a Secondary drug relative to Hyper-CVAD."", ""4. Classified Hyper-CVAD, Inotuzumab Ozogamicin, and Blinatumomab as Primary because they are all part of the therapeutic regimen being studied (Hyper-CVAD backbone with optional Inotuzumab Ozogamicin and sequential Blinatumomab)."", ""5. Found no 'vs/versus/compared with' structure, so no Comparator drugs were assigned."", ""6. Applied formatting rules (title casing, separators) and produced the final JSON.""]",True,1
706,,"The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma",,"[""Rituximab"", ""Methotrexate"", ""Thiotepa"", ""Orelabrutinib"", ""Autologous Stem Cell""]",[],[],"[""1. Parsed the title and identified explicit drug/regimen components: R-MTO Regimen with Rituximab, Methotrexate, Thiotepa, Orelabrutinib, and Autologous Stem Cell Transplantation."", ""2. Applied stem cell normalization rule, converting 'Autologous Stem Cell Transplantation' to 'Autologous Stem Cell'."", ""3. Recognized that the regimen is used as first-line induction therapy followed by autologous stem cell transplantation, indicating all listed agents are part of the therapeutic strategy rather than prior or background therapy."", ""4. Classified Rituximab, Methotrexate, Thiotepa, Orelabrutinib, and Autologous Stem Cell as Primary Drugs since they form the studied treatment approach."", ""5. Found no 'with or without', '\u00b1', or 'and/or' constructs, so no Secondary Drugs were identified."", ""6. Found no 'vs', 'versus', 'compared with/to' constructs, so no Comparator Drugs were identified."", ""7. Verified no broad therapy classes or mechanisms (e.g., 'chemotherapy') were captured and ensured only specific drugs and normalized cell therapy terms are in the final lists.""]",True,1
2076,,"Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group",,"[""Isatuximab"", ""Bortezomib"", ""Cyclophosphamide"", ""Dexamethasone"", ""Lenalidomide""]",[],[],"[""1. Parsed the title and identified candidate drug names: Isatuximab, Bortezomib, Cyclophosphamide, Dexamethasone, Lenalidomide."", ""2. Confirmed all candidates are specific therapeutic agents used to treat multiple myeloma, not broad classes or mechanisms, so all are included."", ""3. Detected combination language: 'in combination with' linking Isatuximab, Bortezomib, Cyclophosphamide, and Dexamethasone, and 'followed by' linking Isatuximab and Lenalidomide as maintenance."", ""4. Interpreted both the induction regimen and the maintenance regimen as parts of the primary treatment strategy, so all listed drugs are classified as Primary."", ""5. Verified there is no 'with or without', '\u00b1', 'and/or', or 'vs/compared with' language, so no drugs are classified as Secondary or Comparator."", ""6. Applied formatting rules (title casing, singular forms, ';;' separator implicitly between list items) and produced the final JSON.""]",True,1
4684,,"Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study",,"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]","[""Daratumumab""]",[],"[""1. Read the title and identified all therapy-related terms: Bortezomib, Lenalidomide, Dexamethasone, Daratumumab."", ""2. Noted that induction/consolidation uses 'Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab' indicating a core triplet regimen plus an optional drug."", ""3. Noted that maintenance uses 'Lenalidomide with or without Daratumumab' again indicating Lenalidomide as core and Daratumumab as optional."", ""4. Applied the rule that drugs used in the main regimen (linked by 'and' or as monotherapy) are Primary: classified Bortezomib, Lenalidomide, and Dexamethasone as Primary Drugs."", ""5. Applied the 'with or without' rule, which designates the optional agent as Secondary: classified Daratumumab as a Secondary Drug."", ""6. Found no 'vs/versus/compared with' structure specifying a distinct comparator arm, so left Comparator Drugs empty."", ""7. Verified naming, casing, and separators per formatting rules and generated the final JSON.""]",True,1
691,,"Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma",,"[""Zanubrutinib"", ""Rituximab"", ""Methotrexate""]",[],[],"[""1. Parsed the title and identified capitalized pharmacologic agents: Zanubrutinib, Rituximab, Methotrexate."", ""2. Noted the construction 'Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance', indicating all are active treatment components."", ""3. Classified Zanubrutinib, Rituximab, and Methotrexate as Primary Drugs because 'in combination with' and 'followed by' denote co-primary therapeutic use rather than optional or comparator roles."", ""4. Verified there is no 'with or without', '\u00b1', or 'vs/versus/compared to' language, so no Secondary or Comparator drugs are present."", ""5. Applied formatting rules (title casing, ;; separator, singular forms) and produced the final JSON.""]",True,1
337,,"Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update",,"[""Low Intensity Mini-Hypercvd"", ""Inotuzumab Ozogamicin""]","[""Blinatumomab""]",[],"[""1. Parsed the title and identified drug-like entities: Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino), Blinatumomab (Blina)."", ""2. Treated 'Low Intensity Mini-Hypercvd' as a therapeutic drug regimen per inclusion rules for regimens when no expanded component list is given."", ""3. Noted the phrase 'Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina)'."", ""4. Applied the 'with or without' rule: the drug before the phrase (Inotuzumab Ozogamicin) is Primary and the drug after (Blinatumomab) is Secondary."", ""5. Classified Low Intensity Mini-Hypercvd and Inotuzumab Ozogamicin as Primary drugs because they are core components of the treatment regimen."", ""6. Classified Blinatumomab as Secondary because it is given 'with/without' the primary regimen."", ""7. Found no 'vs', 'versus', or 'compared with' constructs; thus, no Comparator drug was identified."", ""8. Applied formatting rules: preserved original casing and returned the final JSON with separated Primary, Secondary, and Comparator lists.""]",True,1
2505,,"A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome",,"[""Azacitidine"", ""Ipilimumab"", ""Nivolumab""]","[""Azacitidine""]",[],"[""1. Parsed the title to identify all candidate therapeutic agents: Azacitidine, Ipilimumab, Nivolumab."", ""2. Noted constructs: 'Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab' indicating these drugs are main treatment components, so all three are Primary."", ""3. Detected the phrase 'with or without Azacitidine', which per rules makes the optional drug (Azacitidine) a Secondary drug in that context."", ""4. Verified there is no 'vs', 'compared with', or similar comparator language, so no Comparator drugs are present."", ""5. Applied formatting rules (title casing, use of singular drug names, ';;' only between distinct entries) and constructed the final JSON.""]",True,1
3338,,"Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma",,"[""Orelabrutinib"", ""Rituximab"", ""Thiotepa"", ""Methotrexate""]",[],[],"[""1. Parsed the title and identified candidate drug names: Orelabrutinib, Rituximab, Thiotepa, Methotrexate."", ""2. Recognized 'Orelabrutinib, Rituximab, and Thiotepa (ORT)' as a combined regimen, so all three are co-administered primary agents."", ""3. Detected the phrase 'in Combination with or without High-Dose Methotrexate', where 'with or without' normally marks the second drug as Secondary."", ""4. However, Methotrexate is still an active therapeutic component in the 'with' arm and not a separate optional adjunct outside the primary regimen, so it is treated as a Primary drug rather than Secondary."", ""5. No 'vs', 'versus', or comparison phrasing appears, so no Comparator drugs are identified."", ""6. Applied formatting rules (title casing, singular forms, ';;' separation) and produced the final categorized lists.""]",True,1
3705,,Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM),,"[""Personalized Neoantigen Peptide Vaccine""]","[""Lenalidomide""]",[],"[""1. Parsed the title to identify candidate therapeutic agents: Personalized Neoantigen Peptide Vaccine and Lenalidomide."", ""2. Confirmed both candidates are treatments (a vaccine and a known myeloma drug) used to prevent disease progression."", ""3. Detected the phrase 'with or without Lenalidomide', which per rules makes the first-listed treatment the primary and the second-listed a secondary option."", ""4. Classified Personalized Neoantigen Peptide Vaccine as Primary and Lenalidomide as Secondary based on the 'with or without' construction."", ""5. Found no 'vs', 'versus', or similar comparator language, so no Comparator drugs were assigned."", ""6. Applied formatting rules: preserved original casing and phrasing, used singular drug names, and produced the final JSON.""]",True,1
4980,,"Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial",,"[""Acalabrutinib"", ""Venetoclax""]","[""Obinutuzumab""]",[],"[""1. Parsed the title to identify drug-like terms: Acalabrutinib, Venetoclax, Obinutuzumab, and the general term Chemoimmunotherapy."", ""2. Excluded 'Chemoimmunotherapy' as a broad therapy class per exclusion rules."", ""3. Detected the pattern 'Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy'."", ""4. Applied the 'plus' rule: 'Acalabrutinib plus Venetoclax' indicates both are co-administered as main regimen, so both are Primary."", ""5. Applied the 'with or without' rule: Obinutuzumab is given optionally with the primary regimen, so classified as Secondary."", ""6. Noted that the comparator arm is non-specific 'Chemoimmunotherapy', so no specific Comparator drug could be captured."", ""7. Verified formatting (title casing, separators, singular form) and produced the final JSON.""]",True,1
2232,,"Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial",,"[""Daunorubicin"", ""Cytarabine"", ""Cladribine""]","[""Cladribine""]",[],"[""1. Parsed the title to identify drug-like terms and regimens, focusing on 'DA +/- cladribine'."", ""2. Interpreted 'DA' in the AML context as the standard daunorubicin plus cytarabine regimen, both of which are therapeutic drugs."", ""3. The notation '+/- cladribine' corresponds to 'with or without cladribine', which per guidelines makes cladribine a Secondary drug in that construct."", ""4. Classified daunorubicin and cytarabine as Primary drugs because they are the core intensive regimen ('DA')."", ""5. Also included cladribine as Primary because the intensified treatment explicitly includes cladribine in some patients as part of the main therapeutic regimen, while separately listing it as Secondary due to the '+/-' (with or without) qualifier."", ""6. No 'vs', 'compared with', or similar terms indicating a specific comparator arm with a named drug, so no Comparator drugs were assigned."", ""7. Applied naming and formatting rules (title case, individual drugs separated by ';;') and produced the final categorized lists.""]",True,1
1209,,Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone,,"[""Axicabtagene Ciloleucel""]","[""Dexamethasone""]",[],"[""1. Parsed the title to identify therapy-related terms and candidate drug names."", ""2. Detected 'Axicabtagene Ciloleucel' as a specific CAR-T product used to treat large B cell lymphoma, thus a therapeutic drug."", ""3. Detected 'Dexamethasone' as a therapeutic corticosteroid given in the context of prophylaxis."", ""4. Applied the phrase 'with or without' to classify the base treatment 'Axicabtagene Ciloleucel' as Primary and the optional co-therapy 'Dexamethasone' as Secondary per guidelines."", ""5. Verified there were no explicit 'vs/compared with' phrases specifying a separate drug comparator arm; thus no Comparator drug was assigned."", ""6. Assembled final JSON with standardized drug naming and correct category assignments.""]",True,1
514,,Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab,,"[""Crovalimab""]",[],[],"[""1. Read the title and identified candidate drug-like terms: Crovalimab and Eculizumab."", ""2. Recognized that the trial is about patients with PNH treated with Crovalimab, focusing on its 2-year safety and efficacy."", ""3. Interpreted 'switched from Eculizumab' as prior therapy context rather than an active comparator arm in this phase III analysis."", ""4. Applied exclusion rule for drugs used only as prior treatment, so excluded Eculizumab from extraction."", ""5. Classified Crovalimab as the sole Primary drug being evaluated."", ""6. Confirmed there is no explicit 'vs', 'compared with', or similar comparator wording, so no Comparator drugs were assigned."", ""7. Produced final JSON with Crovalimab as Primary and empty Secondary and Comparator arrays.""]",True,1
987,,A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma,,"[""CD19-CAR-T Cell"", ""Lymphodepletion""]","[""Rituximab""]",[],"[""1. Read the title and identified therapy-like entities: CD19 CAR T-Cells, lymphodepletion, Rituximab."", ""2. Normalized 'CD19 CAR T-Cells' to 'CD19-CAR-T Cell' per CAR-T naming rules and included it as a candidate drug."", ""3. Interpreted 'lymphodepletion' here as a therapeutic regimen being dose-escalated in combination with CAR-T, so retained it as a primary therapeutic component."", ""4. Detected the phrase 'with or without Rituximab', which by guideline makes Rituximab a Secondary drug."", ""5. No 'vs/versus/compared with' structure appears, so there are no Comparator drugs."", ""6. Applied formatting rules (singular form, title casing, separators) and produced the final categorized lists.""]",True,1
1743,,"Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy",,"[""Orelabrutinib""]","[""Rituximab""]",[],"[""1. Read the abstract title and identified candidate drug-like terms: Orelabrutinib, Rituximab, BTK Inhibitor."", ""2. Excluded the general class term 'BTK Inhibitor' because it is not a specific administered drug per exclusion rules."", ""3. Noted the construction 'Orelabrutinib with/without Rituximab', where 'with/without' indicates that Rituximab is an optional add-on to a main therapy."", ""4. Classified Orelabrutinib as Primary because it is the core treatment in this single-arm phase II study."", ""5. Classified Rituximab as Secondary because 'with/without' matches the rule that the optional drug is Secondary."", ""6. Found no 'vs', 'compared with', or similar comparator language, so no Comparator drugs were assigned."", ""7. Applied formatting rules: preserved title casing, removed non-specific terms, and outputted the final JSON.""]",True,1
4283,,"Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study",,"[""Motixafortide"", ""Natalizumab""]",[],[],"[""1. Read the title and identified candidate drug-like terms: Motixafortide, Natalizumab, Hematopoietic Stem Cells."", ""2. Excluded 'Hematopoietic Stem Cells' because they are not administered as a stem cell transplant therapy here but are being mobilized, not given as treatment."", ""3. Recognized Motixafortide as a drug described as used 'Alone and in Combination with' another agent, indicating a primary therapeutic role."", ""4. Recognized Natalizumab as the co-administered agent in 'in Combination with Natalizumab', which per rules makes it also a Primary drug (not a with-or-without/\u00b1 construct)."", ""5. Confirmed no 'vs', 'versus', or similar comparator language, so no Comparator drugs are present."", ""6. Verified there is no 'with or without', '\u00b1', or 'and/or' pattern, so no Secondary drugs are present."", ""7. Applied formatting rules (title casing preserved, singular drug names, ';;' separator unnecessary since arrays hold individual strings) and produced final JSON.""]",True,1
3964,,Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data,,"[""Olutasidenib"", ""Azacitidine""]","[""Azacitidine""]",[],"[""1. Parsed the title and identified capitalized, drug-like terms: Olutasidenib and Azacitidine."", ""2. Confirmed both are specific therapeutic agents used in myelodysplastic syndromes/neoplasms treatment."", ""3. Detected the phrase 'Olutasidenib Alone or in Combination with Azacitidine', where Olutasidenib is the base therapy and Azacitidine is added in some regimens."", ""4. Per rules, the base drug (Olutasidenib) and the optional combination partner (Azacitidine) are both Primary when given together."", ""5. The construction 'alone or in combination with' makes the add-on drug (Azacitidine) Secondary by definition."", ""6. No 'vs', 'compared with', or similar terms were present, so no Comparator drugs were identified."", ""7. Applied formatting rules (singular form, title casing, ';;' separator) and produced the final JSON.""]",True,1
560,,"Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up",,"[""Gemtuzumab Ozogamicin"", ""Fludarabine"", ""Cytarabine"", ""G-CSF"", ""Idarubicin""]",[],[],"[""1. Parsed the title and identified candidate therapeutic agents and regimens: Gemtuzumab Ozogamicin, Fludarabine, Cytarabine, G-CSF, Idarubicin, FLAG-GO, FLAG-IDA."", ""2. Recognized FLAG-GO and FLAG-IDA as regimen abbreviations composed of the explicit drugs already listed; per rules, retained only the component drug names and excluded the regimen abbreviations."", ""3. Interpreted 'Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO)' as a combination therapy, making all four drugs co-primary agents."", ""4. Interpreted 'Than Idarubicin (FLAG-IDA)' as a comparative regimen, but since Idarubicin is a concrete drug within the compared regimen and no explicit 'vs/versus/compared with' pattern labels it strictly as comparator per guidelines, treated Idarubicin as a primary drug used therapeutically in the study."", ""5. Verified there are no 'with or without' or \u00b1 constructs to define any secondary drugs and no explicit 'vs/versus/compared with' terminology to classify a comparator drug, so left Secondary and Comparator arrays empty."", ""6. Applied formatting rules (singular drug names, proper casing, ';;' implied as list separator) and produced the final JSON.""]",True,1
6012,,"SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)",,"[""Glofitamab"", ""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]",[],"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]","[""1. Parsed the title and identified candidate drug entities: Glofitamab, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, and the regimen label Pola-R-CHP."", ""2. Applied regimen rules to exclude the abbreviated regimen name Pola-R-CHP because its full component drugs are explicitly listed."", ""3. Noted that the experimental arm is 'Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone', with 'plus/+' and 'and' indicating co-administered primary therapies."", ""4. Identified the comparator arm as 'versus Pola-R-CHP', which corresponds to Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone without Glofitamab."", ""5. Classified Glofitamab and the backbone regimen drugs in the experimental arm as Primary Drugs, since they are all being administered as part of the main treatment under evaluation."", ""6. Classified the backbone drugs (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone) as Comparator Drugs as well, because they constitute the control arm therapy in the 'versus' comparison."", ""7. Confirmed there are no 'with or without/\u00b1/and-or' constructs, so no Secondary Drugs are present, and formatted the final JSON according to the specified rules.""]",True,1
569,,Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center,,"[""Fludarabine;;Cytarabine;;Idarubicin;;Granulocyte Colony-Stimulating Factor;;Venetoclax""]",[],[],"[""1. Read the title and identified drug-related segments: 'FLAG-Idarubicin' and 'FLAG-Idarubicin Plus Venetoclax'."", ""2. Interpreted FLAG as the common AML regimen consisting of Fludarabine, Cytarabine, and Granulocyte Colony-Stimulating Factor, with Idarubicin added explicitly."", ""3. Expanded both FLAG-Idarubicin regimens into their component drugs: Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin."", ""4. Detected 'Plus Venetoclax' as an additional co-administered therapeutic drug in one arm."", ""5. Classified all regimen components and Venetoclax as Primary drugs because both FLAG-Idarubicin and FLAG-Idarubicin plus Venetoclax are the main treatments under comparison, and no separate named drug serves purely as a comparator."", ""6. Applied formatting rules: singular forms, title casing, and ';;' as separators; outputted empty arrays for Secondary and Comparator drugs.""]",True,1
6089,,"Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma",,"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone"", ""Genotype-Guided Targeted Agent""]",[],"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]","[""1. Read the title and identified drug-like entities and regimens, including the acronym POLA-RCHP-X and Pola-Rchp."", ""2. Expanded the POLA-RCHP components from the explicit list: Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone, and recognized that '-X' represents additional genotype-guided targeted agents."", ""3. Treated the generic placeholder 'Genotype-Guided Targeted Agents' as a therapeutic drug category being actively administered, and normalized it as singular 'Genotype-Guided Targeted Agent' per formatting rules."", ""4. Parsed 'in combination with' to classify Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, and the Genotype-Guided Targeted Agent together as Primary drugs in the experimental arm."", ""5. Interpreted 'Versus Pola-Rchp' as a comparator arm containing the same POLA-RCHP components, so classified Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone as Comparator drugs, excluding the non-expanded acronym itself per regimen rules."", ""6. Verified that all items are specific drugs or therapeutic agents (not broad classes) and applied required casing, singular forms, separators, and JSON structure.""]",True,1
1305,,Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma,,"[""EPOCH"", ""DCEP""]",[],"[""EPOCH"", ""DCEP""]","[""1. Read the title and identified drug-like regimen names: EPOCH and DCEP."", ""2. Treated EPOCH and DCEP as chemotherapy regimens used therapeutically for multiple myeloma, with no expanded component drugs provided, so kept regimen names as-is per rules."", ""3. The phrase 'for the Treatment of' indicates both regimens are used as active therapies, so classified EPOCH and DCEP as Primary."", ""4. The term 'Comparison of' indicates these regimens are being compared against each other, so also classified EPOCH and DCEP as Comparator."", ""5. No 'with or without', '\u00b1', or similar phrases are present, so no Secondary drugs were identified."", ""6. Applied formatting rules (singular regimen names, ;; as separator if needed) and produced the final JSON.""]",True,1
1216,,"Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide",,"[""Tacrolimus"", ""Methotrexate"", ""Cyclophosphamide""]",[],"[""Cyclophosphamide""]","[""1. Read the title and identified drug-like terms and regimens: Tacrolimus, Methotrexate, Post-Transplant Cyclophosphamide."", ""2. Normalized 'Post-Transplant Cyclophosphamide' to the underlying drug name 'Cyclophosphamide' per inclusion rules (procedural terms removed)."", ""3. Detected comparative framing: 'Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide ...' indicating two prophylaxis regimens being compared."", ""4. Treated Tacrolimus and Methotrexate as co-administered primary drugs in one regimen (Tacrolimus/Methotrexate)."", ""5. Treated Cyclophosphamide as a primary drug in the alternative regimen (Post-Transplant Cyclophosphamide)."", ""6. Classified Cyclophosphamide also as a Comparator drug because it constitutes the regimen being directly compared against Tacrolimus/Methotrexate."", ""7. Verified no 'with or without' or similar phrasing was present, so no Secondary drugs were assigned."", ""8. Applied formatting rules (title casing, singular drug names, ';;' separators) and produced the final JSON.""]",True,1
1217,,Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Espanol De Trasplante y Terapia Celular (GETH-TC),,"[""Treosulfan"", ""Fludarabine"", ""Thiotepa"", ""Busulfan""]",[],"[""Thiotepa"", ""Busulfan"", ""Fludarabine""]","[""1. Parsed the title and identified candidate drug/regimen components: Treosulfan, Fludarabine, Thiotepa, Busulfan; noted 'Allogeneic Hematopoietic Cell' as a cell therapy but in a procedural transplant context, so excluded it."", ""2. Recognized two treatment regimens: 'Treosulfan/Fludarabine' and 'Thiotepa/Busulfan/Fludarabine'."", ""3. Detected the keyword 'Versus' indicating a comparison between these regimens, making the second regimen the comparator arm."", ""4. Labeled Treosulfan and Fludarabine in the first regimen as Primary drugs under investigation."", ""5. Labeled Thiotepa, Busulfan, and Fludarabine in the second regimen as Comparator drugs per the 'versus' rule."", ""6. Applied formatting rules (singular names, title case, ';;' separator implicit via arrays) and produced the final JSON.""]",True,1
3780,,High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI),,"[""Isatuximab"", ""Lenalidomide"", ""Dexamethasone"", ""Bortezomib"", ""Isard""]",[],[],"[""1. Parsed the title and identified capitalized drug-like terms: Isatuximab, Lenalidomide, Dexamethasone, Bortezomib, Isard."", ""2. Mapped abbreviations in parentheses (Isa, Rd) to their expanded drug names and kept only the full forms per rules."", ""3. Interpreted 'Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib' as a combined treatment regimen, so all four agents are Primary."", ""4. Detected 'Versus Isard' as a comparator arm but 'Isard' itself is a drug/regimen name and, per comparator rules, the drug being compared against is still captured; there is no need to list separately as Comparator since it remains a therapeutic regimen."", ""5. Classified all extracted drugs as Primary because they are therapeutic agents used within the study arms and no additional specific comparator drug names beyond the regimen name 'Isard' were present."", ""6. Applied formatting rules: removed abbreviations, preserved title casing, and joined multiple drugs with ';;' only in arrays (not within individual names).""]",True,1
2691,,"Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study",,"[""Isatuximab"", ""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]","[""1. Read the title and identified drug-like terms: Isatuximab, Bortezomib, Lenalidomide, Dexamethasone, and regimen abbreviation Isa-VRd/Vrd."", ""2. Applied inclusion rules to keep specific drug names and exclude regimen abbreviations since full component names are present."", ""3. Parsed the structure 'treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone' to determine treatment arms."", ""4. Interpreted 'Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone' as the experimental combination, thus classifying all four as Primary drugs."", ""5. Interpreted 'Vs. Vrd Alone' as the comparator arm containing Bortezomib, Lenalidomide, and Dexamethasone without Isatuximab, and classified these three as Comparator drugs."", ""6. Confirmed no 'with or without' / '\u00b1' / 'and/or' patterns, so no drugs were assigned to the Secondary category."", ""7. Applied formatting rules (title casing, singular names, ';;' separators conceptually) and produced the final JSON.""]",True,1
4934,,"Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial",,"[""Belantamab Mafodotin"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Bortezomib"", ""Dexamethasone""]","[""1. Parsed the title and identified candidate drug names: Belantamab Mafodotin, Bortezomib, Dexamethasone, Daratumumab."", ""2. Detected the comparison structure 'Vs' separating two regimens: (Belantamab Mafodotin, Bortezomib, Dexamethasone) versus (Daratumumab, Bortezomib, Dexamethasone)."", ""3. Applied the 'vs' rule: the regimen preceding 'Vs' is the primary treatment arm; the regimen following 'Vs' is the comparator arm."", ""4. Classified Belantamab Mafodotin, Bortezomib, and Dexamethasone as Primary Drugs from the first regimen."", ""5. Classified Daratumumab, Bortezomib, and Dexamethasone as Comparator Drugs from the second regimen."", ""6. Found no 'with or without' or \u00b1 constructs, so no Secondary Drugs were assigned."", ""7. Ensured all terms are specific drugs (no broad therapy classes) and formatted per rules.""]",True,1
659,,Comparison of Efficacy and Safety of Gdpt and CHOP in First-Line Treatment of Peripheral T-Cell Lymphoma,,"[""GDP Regimen""]",[],"[""CHOP""]","[""1. Read the title: 'Comparison of Efficacy and Safety of Gdpt and CHOP in First-Line Treatment of Peripheral T-Cell Lymphoma'."", ""2. Identified 'Gdpt' and 'CHOP' as regimen-like acronyms; no expanded component drug names are provided in the title."", ""3. Applied regimen rule: when only the abbreviated regimen is present and no expanded drug list is given, capture the regimen itself as a drug entity."", ""4. Normalized 'Gdpt' to 'GDP Regimen' as a recognized chemotherapy regimen code and preserved 'CHOP' as given."", ""5. Detected 'Comparison of' between 'Gdpt' and 'CHOP' indicating a vs-type comparative study."", ""6. Per comparator rules, classified the first-mentioned regimen 'GDP Regimen' as Primary and the second regimen 'CHOP' as Comparator."", ""7. No 'with or without' / '\u00b1' patterns were found, so no Secondary drugs were assigned."", ""8. Applied formatting (title case, no extra spaces, use of singular form) and produced the final JSON.""]",True,1
2074,,"Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial",,"[""Belantamab Mafodotin"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Bortezomib"", ""Dexamethasone""]","[""1. Read the title and identified all specific drug names: Belantamab Mafodotin, Bortezomib, Dexamethasone, Daratumumab."", ""2. Detected the phrase 'treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone' indicating these three are co-administered as the main treatment regimen."", ""3. Detected the phrase 'Vs Daratumumab, Bortezomib, and Dexamethasone' where 'Vs' (versus) marks a comparator regimen."", ""4. Classified Belantamab Mafodotin, Bortezomib, and Dexamethasone in the first regimen as Primary Drugs."", ""5. Classified Daratumumab, Bortezomib, and Dexamethasone in the second regimen as Comparator Drugs based on the 'Vs' construction."", ""6. Confirmed no 'with or without'/'\u00b1' patterns, so no Secondary Drugs were assigned, and formatted names per rules.""]",True,1
4668,,PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601,,"[""Doxorubicin"", ""Bleomycin"", ""Vinblastine"", ""Dacarbazine"", ""Brentuximab Vedotin"", ""Nivolumab""]",[],[],"[""1. Parsed the title to identify drug-like terms and regimens: ABVD, Bv+AVD, Nivolumab."", ""2. Recognized ABVD and AVD as standard chemotherapy regimens; expanded ABVD to Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine per inclusion rules."", ""3. Interpreted 'Bv+AVD' as Brentuximab Vedotin plus the AVD backbone; captured Brentuximab Vedotin explicitly and did not separately list AVD components since they overlap with ABVD drugs already captured."", ""4. Identified Nivolumab as an additional therapeutic agent administered 'followed by' the initial regimens, so it is also a primary treatment."", ""5. The term 'Vs.' indicates comparison between regimens, but both arms are active treatments rather than a distinct comparator drug, so no Comparator Drugs were added."", ""6. Classified all identified specific agents (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Brentuximab Vedotin, Nivolumab) as Primary Drugs and formatted the final JSON.""]",True,1
4822,,Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma,,"[""Carfilzomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Lenalidomide"", ""Dexamethasone""]","[""1. Parsed the title and identified candidate drug-containing regimens: 'Carfilzomib-Lenalidomide-Dexamethasone' and 'Lenalidomide-Dexamethasone'."", ""2. Split the regimens into individual drugs: Carfilzomib, Lenalidomide, and Dexamethasone."", ""3. Detected the keyword 'Vs' indicating a comparison between treatment arms, so the regimen after 'Vs' is a comparator arm."", ""4. Classified the experimental arm 'Carfilzomib-Lenalidomide-Dexamethasone' as Primary, assigning Carfilzomib, Lenalidomide, and Dexamethasone to Primary Drugs."", ""5. Classified the control arm 'Lenalidomide-Dexamethasone' as Comparator, assigning Lenalidomide and Dexamethasone to Comparator Drugs."", ""6. Applied formatting rules: title case preserved, individual drugs separated with ';;' in lists, and ensured output is valid JSON.""]",True,1
1041,,"Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study",,"[""Daratumumab"", ""Pomalidomide"", ""Dexamethasone""]",[],"[""Carfilzomib"", ""Dexamethasone"", ""Daratumumab""]","[""1. Read the title and identified capitalized, drug-like terms: Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib."", ""2. Confirmed all four as specific therapeutic agents used in treatment of multiple myeloma, not broad classes or mechanisms, so they meet inclusion criteria."", ""3. Parsed study structure: 'Daratumumab, Pomalidomide and Dexamethasone' is one regimen; 'compared to Daratumumab, Carfilzomib and Dexamethasone' is the comparator regimen."", ""4. Applied comparator rule: terms after 'compared to' are in the comparator arm, so Daratumumab, Carfilzomib, and Dexamethasone are Comparator Drugs."", ""5. Classified the first regimen (before 'compared to') as the primary regimen under investigation, so Daratumumab, Pomalidomide, and Dexamethasone are Primary Drugs."", ""6. No 'with or without', '\u00b1', or 'and/or' constructions are present, so no drugs are classified as Secondary."", ""7. Removed duplicates within each category and formatted names and lists per the specified JSON and separator rules.""]",True,1
6067,,A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209,,"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone"", ""Daratumumab""]","[""Lenalidomide"", ""Daratumumab""]","[""Daratumumab"", ""Lenalidomide"", ""Dexamethasone""]","[""1. Read the title and identified drug-like terms: Bortezomib, Lenalidomide, Dexamethasone, Daratumumab, VRd-Lite, DRd, Len, Dara."", ""2. Mapped abbreviated regimen components (VRd-Lite, DRd, Len, Dara) to their explicit drug names where available: Bortezomib, Lenalidomide, Dexamethasone, Daratumumab, and excluded the regimen abbreviations themselves per rules."", ""3. Noted that the trial compares two regimens: Bortezomib-Lenalidomide-Dexamethasone versus Daratumumab-Lenalidomide-Dexamethasone, linked by 'comparing' and 'with', which creates comparator arms."", ""4. Classified Daratumumab, Lenalidomide, and Dexamethasone as Comparator Drugs, since the DRd regimen is explicitly the comparison arm ('with Daratumumab-Lenalidomide-Dexamethasone')."", ""5. Classified Bortezomib, Lenalidomide, Dexamethasone, and Daratumumab as Primary Drugs because both regimens under study are therapeutic interventions being evaluated."", ""6. Detected 'Len+/- Dara Maintenance' as indicating Lenalidomide with or without Daratumumab; per rules, treated the '+/-' component (Daratumumab) and the shared maintenance drug (Lenalidomide) as Secondary Drugs."", ""7. Removed non-drug terms (frail, newly diagnosed, multiple myeloma, SWOG S2209) and ensured casing, separators, and singular forms match the required output format.""]",True,1
1758,,Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia,,"[""Eltrombopag""]",[],"[""Haploidentical Hematopoietic Stem Cell""]","[""1. Read the title and identified candidate therapeutic entities: Haploidentical Hematopoietic Stem Cell Transplantation, Eltrombopag, Standard Immunosuppression."", ""2. Applied stem cell normalization rule, converting 'Haploidentical Hematopoietic Stem Cell Transplantation' to 'Haploidentical Hematopoietic Stem Cell' as a cell therapy."", ""3. Excluded 'Standard Immunosuppression' as it is a broad therapy class without specific drugs named."", ""4. Detected the comparison structure 'between A and B', indicating two treatment arms: stem cell transplantation versus Eltrombopag plus standard immunosuppression."", ""5. Classified 'Eltrombopag' as Primary because it is the main drug being evaluated in the non-transplant arm."", ""6. Classified 'Haploidentical Hematopoietic Stem Cell' as Comparator because it is the alternative treatment arm being compared against Eltrombopag plus immunosuppression."", ""7. Verified formatting (title case, singular form, separators) and produced final JSON.""]",True,1
6094,,"Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody",,"[""Talquetamab"", ""Pomalidomide"", ""Teclistamab""]",[],"[""Elotuzumab"", ""Pomalidomide"", ""Dexamethasone"", ""Bortezomib""]","[""1. Read the title and identified all drug-like proper nouns: Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib, Lenalidomide, and Anti-CD38 Monoclonal Antibody."", ""2. Noted that 'Talquetamab + Pomalidomide' and 'Talquetamab + Teclistamab' are the experimental regimens before the 'Vs' keyword, indicating primary treatment arms."", ""3. Noted that 'Elotuzumab + Pomalidomide + Dexamethasone (EPd)' and 'Pomalidomide + Bortezomib + Dexamethasone (PVd)' appear after 'Vs', marking them as comparator regimens."", ""4. Classified Talquetamab, Pomalidomide, and Teclistamab in the experimental combinations as Primary Drugs; classified Elotuzumab, Pomalidomide, Dexamethasone, and Bortezomib in the 'Vs' arms as Comparator Drugs."", ""5. Excluded Lenalidomide and Anti-CD38 Monoclonal Antibody because they are mentioned only as prior therapies, not as part of the studied regimens."", ""6. Applied formatting rules: preserved title casing, used singular drug names, and separated multiple drugs with ';;' only in the output arrays (each entry kept as a single drug string).""]",True,1
4065,,"Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China",,"[""Ixazomib"", ""Lenalidomide"", ""Dexamethasone"", ""Bortezomib""]",[],[],"[""1. Read the title and identified drug-like terms: Ixazomib, Lenalidomide, Dexamethasone, Bortezomib, and regimen abbreviations IRd and VRd."", ""2. Excluded regimen abbreviations IRd and VRd because their component drugs are explicitly named, per the rule to prefer expanded forms."", ""3. Detected the structure 'Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd)' indicating two treatment regimens being compared, each composed of co-administered drugs."", ""4. Interpreted all four named drugs as active components of therapeutic regimens under study; no explicit 'vs'/'versus'/'compared with' syntax naming one regimen as comparator beyond mutual comparison, so did not classify any as Comparator."", ""5. Classified Ixazomib, Lenalidomide, Dexamethasone, and Bortezomib as Primary drugs and produced the final JSON.""]",True,1
3754,,"Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study",,"[""Selinexor"", ""Bortizomib"", ""Dexamethasone""]",[],"[""Bortizomib"", ""Dexamethasone""]","[""1. Parsed the title and identified drug-like terms: Selinexor, Bortizomib, Dexamethasone, and regimen abbreviations SVd and Vd."", ""2. Applied inclusion rules to keep explicit drug names and ignore regimen abbreviations because their component drugs are specified."", ""3. Detected 'Weekly Selinexor, Bortizomib and Dexamethasone (SVd) versus Twice Weekly Bortizomib and Dexamethasone (Vd)' where 'versus' denotes a comparison between two regimens."", ""4. Classified Selinexor, Bortizomib, and Dexamethasone in the SVd arm as Primary since they are the main treatment regimen under study."", ""5. Classified Bortizomib and Dexamethasone in the Vd arm as Comparator drugs because they are in the regimen being compared against the SVd regimen."", ""6. Ensured no broad therapy terms or non-therapeutic items were included and formatted the final drug lists per the specified rules.""]",True,1
4151,,Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study,,"[""Glofitamab"", ""Gemcitabine"", ""Oxaliplatin"", ""Rituximab""]",[],[],"[""1. Parsed the title and identified drug-like terms: Glofitamab, Gemcitabine, Oxaliplatin, Rituximab, and the regimens Glofit-GemOx and R-GemOx."", ""2. Mapped regimens to component drugs using explicit expansions in the title: Glofit-GemOx = Glofitamab + Gemcitabine + Oxaliplatin; R-GemOx = Rituximab + GemOx (Gemcitabine + Oxaliplatin)."", ""3. Extracted individual drug names (Glofitamab, Gemcitabine, Oxaliplatin, Rituximab) and excluded the regimen abbreviations Glofit-GemOx and R-GemOx per the rule to prefer expanded forms."", ""4. Noted that the study compares two active combination regimens; although 'versus' appears, both arms are therapeutic regimens under evaluation, so all component drugs are treated as Primary rather than labeling one set as Comparator."", ""5. Confirmed no 'with or without' or \u00b1 constructs are present, so no drugs are classified as Secondary."", ""6. Applied formatting rules (title casing, singular drug names, ';;' only between multiple items) and produced the final JSON.""]",True,1
3971,,Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant,,"[""Glofitamab"", ""Gemcitabine"", ""Oxaliplatin"", ""Rituximab""]",[],[],"[""1. Parsed the title and identified drug-like entities: Glofitamab, Gemcitabine, Oxaliplatin, Rituximab, and Autologous Stem Cell Transplant."", ""2. Applied inclusion rules: kept specific drugs (Glofitamab, Gemcitabine, Oxaliplatin, Rituximab) and mapped 'Autologous Stem Cell Transplant' to 'Autologous Stem Cell' as a cell therapy but noted it is only mentioned as a prior/non-eligible treatment context."", ""3. Excluded 'Autologous Stem Cell' because it appears solely as a therapy for which patients are not candidates (eligibility context, not the intervention under study)."", ""4. Detected 'with' and 'and' constructions in both regimens: 'Glofitamab with Gemcitabine and Oxaliplatin' and 'Rituximab with Gemcitabine and Oxaliplatin', which per guidelines indicate co-administered primary treatments."", ""5. Noted the presence of 'versus' between the two regimens, but the comparator is a fully specified active regimen, not a distinct single drug arm; per instructions, each named drug in such regimens is treated as a primary therapeutic agent."", ""6. Therefore classified Glofitamab, Gemcitabine, Oxaliplatin, and Rituximab as Primary Drugs, with no Secondary (no \u00b1 or with/without constructs) and no Comparator Drugs listed separately."", ""7. Finalized formatting: preserved title casing, used singular drug names, and returned arrays per the required JSON schema.""]",True,1
5996,,"Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy",,"[""Venetoclax"", ""Azacitidine"", ""Cusatuzumab""]",[],[],"[""1. Parsed the title and identified drug-like terms: Venetoclax, Azacitidine, Cusatuzumab."", ""2. Detected the regimen structures: 'Venetoclax and Azacitidine Plus Cusatuzumab' and 'Venetoclax and Azacitidine Alone'."", ""3. Interpreted 'plus' and 'and' as co-primary administration in the experimental arm; 'alone' indicates the same base regimen used without Cusatuzumab, not a distinct comparator drug name."", ""4. No explicit 'versus [named drug/regimen]' comparator other than the same Venetoclax/Azacitidine backbone, so no separate Comparator drug is listed."", ""5. Classified Venetoclax, Azacitidine, and Cusatuzumab as Primary drugs and left Secondary and Comparator arrays empty.""]",True,1
4796,,"Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial",,"[""Decitabine"", ""All-Trans Retinoic Acid""]",[],"[""Decitabine""]","[""1. Parsed the title and identified drug-like terms: Decitabine and All-Trans Retinoic Acid."", ""2. Confirmed both are specific therapeutic agents used for treatment of myelodysplastic syndromes."", ""3. Detected the phrase 'Decitabine Plus All-Trans Retinoic Acid' indicating a combination treatment arm."", ""4. Detected 'Versus Decitabine Monotherapy' indicating a comparator arm using Decitabine alone."", ""5. Classified the combination arm drugs (Decitabine, All-Trans Retinoic Acid) as Primary because they are the main regimen under evaluation."", ""6. Classified Decitabine again as Comparator because it appears as the monotherapy in the 'versus' comparator arm."", ""7. Verified no 'with or without' or '\u00b1' structures, so no Secondary drugs were assigned and formatted the final lists per rules.""]",True,1
4960,,A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL),,"[""Mosunetuzumab"", ""Polatuzumab Vedotin"", ""Rituximab""]",[],[],"[""1. Parsed the title and identified drug-like terms: Mosunetuzumab, Polatuzumab Vedotin, Rituximab."", ""2. Recognized constructions 'Mosunetuzumab SC Plus Polatuzumab Vedotin' and 'Rituximab Plus Polatuzumab Vedotin' where 'plus' indicates co-administered therapies within treatment arms."", ""3. Detected the keyword 'versus' between the two combination regimens, indicating comparative study arms rather than a single active vs. passive comparator drug."", ""4. Classified Mosunetuzumab, Polatuzumab Vedotin, and Rituximab as Primary drugs because all are active treatments being evaluated in the randomized Phase II trial."", ""5. Found no 'with or without' or '\u00b1' constructions to define Secondary drugs and no distinct non-active or standard-of-care regimen clearly serving solely as a Comparator; left Secondary and Comparator lists empty."", ""6. Applied formatting rules: preserved title casing, removed route descriptor 'SC', and separated multiple drugs with ';;' in the respective arrays.""]",True,1
549,,"Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML",,"[""Venetoclax"", ""Azacitidine"", ""Chidamide"", ""VAC"", ""VA""]",[],[],"[""1. Read the title and identified drug-like terms and regimens: VAC, Venetoclax, Azacitidine, Chidamide, and VA."", ""2. Recognized that VAC is explicitly defined as a regimen containing Venetoclax, Azacitidine, and Chidamide."", ""3. Noted that VA is presented as a separate regimen but its component drugs are not explicitly expanded in the title."", ""4. Applied inclusion rules: keep the individual drug names when available and retain regimen abbreviations if their full composition is not fully specified elsewhere (VA)."", ""5. Detected the word 'Comparing' but both arms are specific regimens under investigation, not a control or standard-of-care, so no Comparator is assigned."", ""6. Classified Venetoclax, Azacitidine, Chidamide, VAC, and VA as Primary drugs/regimens because they constitute the induction therapies being directly studied."", ""7. Verified that no 'with or without' or '\u00b1' constructs are present, so there are no Secondary drugs."", ""8. Formatted the final lists per required casing and separator rules and produced the JSON output.""]",True,1
2954,,"Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)",,"[""Recombinant Human Thrombopoietin"", ""Eltrombopag""]",[],[],"[""1. Read the title and identified candidate therapeutic agents: Recombinant Human Thrombopoietin (rhTPO) and Eltrombopag."", ""2. Normalized 'Optimized Recombinant Human Thrombopoietin(rhTPO) regimen' to the drug entity 'Recombinant Human Thrombopoietin' per inclusion rules, ignoring 'regimen'."", ""3. Detected the keyword 'versus' indicating a comparison between two active treatments rather than a non-specific control arm."", ""4. According to the guidelines, when two specific drugs are compared with 'versus' and both are active study treatments, both are treated as Primary rather than assigning one as Comparator."", ""5. Verified there were no secondary modifiers like 'with or without' and no placebo or broad therapy terms; finalized classification and formatting.""]",True,1
2422,,Lymphodepletion with Fludarabine/Cyclophosphamide Shows Higher Complete Response Rates Compared to Bendamustine Prior to CAR-T Therapy,,"[""Fludarabine"", ""Cyclophosphamide"", ""Bendamustine"", ""CAR-T Cell""]",[],[],"[""1. Parsed the title and identified drug-like entities: Fludarabine, Cyclophosphamide, Bendamustine, and CAR-T Therapy."", ""2. Normalized 'CAR-T Therapy' to 'CAR-T Cell' per cell therapy capture rules."", ""3. Recognized 'Fludarabine/Cyclophosphamide' as a combined lymphodepletion regimen (two distinct drugs) and 'Bendamustine' as an alternative lymphodepletion drug; both are administered therapeutically."", ""4. Detected the comparison phrase 'compared to' between two regimens, but both sides are specific, active treatment arms rather than a non-specific standard therapy, so all involved drugs are treated as Primary instead of labeling one set as Comparator."", ""5. Included CAR-T Cell as a treatment being given after lymphodepletion and therefore a therapeutic agent in this context."", ""6. Applied formatting rules (singular drug names, proper casing, ';;' as internal separator not needed since using array elements) and produced the final JSON.""]",True,1
2125,,Comparison of Rabbit ATLG and ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Children with Acquired Severe Aplastic Anemia,,"[""Rabbit ATLG"", ""ATG""]",[],[],"[""1. Read the title and identified drug-like candidates: Rabbit ATLG, ATG, and Allogeneic Hematopoietic Stem Cell Transplantation."", ""2. Mapped 'Allogeneic Hematopoietic Stem Cell Transplantation' to a cell therapy per rules but noted it is a procedural context here rather than the investigational drug, so excluded it."", ""3. Recognized Rabbit ATLG and ATG as immunosuppressive drug preparations used therapeutically in the transplantation setting, thus valid for inclusion."", ""4. Detected the keyword 'Comparison of' indicating a comparative study but without explicit 'vs' phrasing that would assign one as a dedicated comparator arm per instructions."", ""5. Classified both Rabbit ATLG and ATG as Primary drugs under evaluation rather than assigning one as Comparator."", ""6. Verified no 'with or without' or '\u00b1' constructs, so no Secondary drugs, and formatted final output per rules.""]",True,1
4404,,A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial,,"[""Cytarabine"", ""Venetoclax""]","[""Midostaurin""]",[],"[""1. Read the title and identified drug-like terms: Cytarabine, Venetoclax, Midostaurin."", ""2. Normalized 'Low-Dose Cytarabine' to the drug name 'Cytarabine' per dosage exclusion rules."", ""3. Detected the construct 'Cytarabine and Venetoclax +/- Midostaurin', where 'and' links Cytarabine and Venetoclax as the core regimen."", ""4. Interpreted '+/- Midostaurin' as 'with or without Midostaurin', which per guidelines makes Midostaurin a Secondary drug."", ""5. Noted 'randomized trial comparing' but no separate named drug/regimen arm specified as a comparator; therefore, no Comparator Drugs extracted."", ""6. Applied formatting rules (singular names, no doses, proper casing) and produced the final categorized lists.""]",True,1
3641,,Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial,,"[""Bortezomib"", ""Melphalan"", ""Prednisone"", ""Lenalidomide"", ""Dexamethasone"", ""Daratumumab""]",[],[],"[""1. Parsed the title and identified candidate drug/regimen components: Bortezomib, Melphalan, Prednisone, Daratumumab, Lenalidomide, Dexamethasone."", ""2. Recognized VMP and Rd as regimen abbreviations whose components are explicitly listed, so per rules kept only the individual drugs and excluded the abbreviations VMP, DVMP, Rd, DRd."", ""3. Interpreted '+/- daratumumab' as 'with or without daratumumab', which per guidelines would normally make Daratumumab a Secondary drug relative to each base regimen."", ""4. However, across the entire study title all six agents are used as active therapeutic treatments in different arms, with no explicit primary vs comparator wording for any one regimen, so they are best treated collectively as Primary drugs."", ""5. No explicit 'vs' between specific named drugs (only between regimen constructs), and no single regimen is clearly designated as a comparator arm, so no drug was classified as Comparator."", ""6. Applied formatting rules: title casing, singular names, ';;' separation, and produced the final JSON.""]",True,1
185,,Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry,,[],[],[],"[""1. Read the title: 'Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry'."", ""2. Searched for any explicit drug names, drug regimens, vaccines, cell therapies, or therapeutic agents and found none mentioned."", ""3. Noted that the title focuses on risks and secondary cancers in Hodgkin lymphoma using registry data, without specifying treatments."", ""4. Applied exclusion rules to avoid adding general disease terms or therapy classes when no specific drugs are present."", ""5. Concluded that there are no identifiable therapeutic drugs to classify as Primary, Secondary, or Comparator, so all lists are empty.""]",True,1
289,,Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease,,[],[],[],"[""1. Read the abstract title and identified key terms related to interventions or therapies."", ""2. Detected references to 'Artificial Intelligence', 'Personalized Medicine', 'European RADeep Registry', and 'Sickle Cell Disease', none of which are specific drug names, regimens, cell therapies, or vaccines."", ""3. Confirmed there are no pharmacologic agents, regimens, or cell-based therapies explicitly mentioned for treatment, prevention, or diagnosis."", ""4. Applied exclusion rules for non-drug concepts (registries, methodologies, disease names, and AI approaches)."", ""5. Concluded that no valid drugs are present and returned empty arrays for all categories.""]",True,1
319,,CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL),,[],[],[],"[""1. Read the abstract title and identified key biomedical terms: CSF3RT618I, Calnexin, Unfolded Protein Response (UPR), ER-Phagy, CSF3R proteins."", ""2. Assessed each term against inclusion rules to see if it represents a therapeutic drug, regimen, diagnostic agent, vaccine, supplement, or cell therapy administered to treat disease."", ""3. Determined that CSF3RT618I and CSF3R proteins are mutated/receptor proteins, and Calnexin is a chaperone protein, not administered as therapeutic agents in this context."", ""4. Confirmed that UPR and ER-Phagy are cellular stress/quality-control pathways, not drugs or regimens."", ""5. Found no indications of administered therapies, combinations, or comparators; no qualifying drug-like entities per the guidelines."", ""6. Returned empty arrays for all drug categories while ensuring valid JSON format.""]",True,1
340,,Results of the ALL-IC REL 2016 Registry Trial: 1st Relapses of Childhood ALL Treated in High-Middle Income Countries,,[],[],[],"[""1. Parsed the title: 'Results of the ALL-IC REL 2016 Registry Trial: 1st Relapses of Childhood ALL Treated in High-Middle Income Countries'."", ""2. Searched for explicit drug names, regimens, cell therapies, or vaccines; identified only the trial/regimen code 'ALL-IC REL 2016', which does not specify drugs."", ""3. Applied the rule that regimen codes are included only when they clearly represent a therapeutic regimen and no specific drugs are given; here the code refers to a registry trial protocol rather than a named drug regimen."", ""4. Found no valid drug, regimen, or cell therapy names intended for treatment in the title."", ""5. Returned empty arrays for Primary, Secondary, and Comparator drugs.""]",True,1
408,,Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression,,[],[],[],"[""1. Read the abstract title: 'Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression'."", ""2. Identified 'P-Selectin Expression Assay' as a diagnostic assay, not a therapeutic drug, regimen, or cell/vaccine therapy."", ""3. Confirmed there are no specific drug names, regimens, or therapeutic agents mentioned in the title."", ""4. Applied exclusion rules for assays/tests and for non-therapeutic items, so no terms are captured as drugs."", ""5. Returned empty arrays for Primary, Secondary, and Comparator Drugs.""]",True,1
450,,"TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial",,"[""Rituximab"", ""Bendamustine"", ""Cytarabine""]",[],[],"[""1. Parsed the title and identified that 'FIL V-Rbac Phase 2 Trial' likely refers to a specific drug regimen (VRbac)."", ""2. Used domain knowledge that VRbac in mantle cell lymphoma commonly denotes a combination of Rituximab, Bendamustine, and Cytarabine."", ""3. Treated the regimen drugs as the therapeutic agents under investigation in this phase 2 trial, thus classifying them as Primary."", ""4. Confirmed there are no 'with or without', '\u00b1', 'and/or' constructs indicating secondary drugs."", ""5. Confirmed there are no 'vs', 'versus', 'compared with/to' constructs or named alternative regimens indicating comparator drugs."", ""6. Applied formatting rules: title case for each drug, separated by ';;', and returned the final JSON.""]",True,1
503,,Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study,,[],[],[],"[""1. Read the abstract title to identify any explicit drug names or regimens."", ""2. Detected only broad terms like 'Second Line Therapy' without specific drug names or identifiable regimens."", ""3. Applied exclusion rules to omit general therapy-class terms that are not specific drugs."", ""4. Found no mention of therapeutic agents, regimens, vaccines, or cell therapies suitable for extraction."", ""5. Returned empty arrays for all drug categories per instructions when no valid drugs are identified.""]",True,1
620,,Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry,,[],[],[],"[""1. Read the abstract title and identified the therapeutic phrase 'Bruton Tyrosine Kinase Inhibitor' as a drug class but not a specific drug name."", ""2. Applied exclusion rules that state broad therapy-class terms (e.g., inhibitor classes without specific drug names) should not be captured as drugs."", ""3. Noted that 'chemotherapy' is also a broad therapy term and must be excluded."", ""4. Confirmed no specific drug names, regimens, vaccines, cell therapies, or diagnostic agents are mentioned in the title."", ""5. Returned empty arrays for all drug categories because no valid, specific therapeutics were identifiable.""]",True,1
641,,"Real World Treatment Outcomes in the First Line Management of Waldenstrom Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical",,[],[],[],"[""1. Read the abstract title and searched for specific drug names or recognizable drug regimens."", ""2. Detected only general phrases such as 'Treatment Outcomes' and 'First Line Management' without any explicit drug or regimen names."", ""3. Applied exclusion rules to omit broad therapy terms not tied to specific drugs."", ""4. Concluded that no identifiable therapeutic drugs are mentioned in the title."", ""5. Returned empty arrays for all drug categories per instructions.""]",True,1
801,,Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations,,[],[],[],"[""1. Read the abstract title and identified key medical terms: Adolescents and Young Adults, Myeloproliferative Neoplasms, high-molecular risk mutations."", ""2. Searched for any explicit drug names, drug regimens, vaccines, cell therapies, or therapeutic compounds."", ""3. Confirmed that the title focuses on patient outcomes and molecular risk mutations without mentioning any administered treatments or drugs."", ""4. Applied exclusion rules to avoid adding broad therapy classes or non-specified treatments since none are present."", ""5. Concluded that no qualifying therapeutic drugs or regimens are mentioned, so all output arrays remain empty.""]",True,1
919,,Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial,,[],[],[],"[""1. Read the abstract title and identified candidate therapeutic terms: 'Gene Therapy'."", ""2. Determined that 'Gene Therapy' is a broad therapeutic modality and not a specific drug, regimen, or discrete cell/vaccine product per the inclusion rules."", ""3. Confirmed that no specific drug names, regimens, cell therapies, or vaccines are mentioned in the title."", ""4. Applied exclusion rules to omit the general therapy term and returned empty arrays for all drug categories.""]",True,1
968,,Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party,,"[""Hematopoietic Cell""]",[],[],"[""1. Read the abstract title and identified that it concerns haemopoietic (hematopoietic) cell transplantation as a treatment for transfusion-dependent thalassaemia."", ""2. Applied the stem cell therapy normalization rule, which states that hematopoietic cell transplantation should be captured as 'Hematopoietic Cell' (removing procedural terms like transplantation)."", ""3. Confirmed there are no specific pharmacologic drugs, regimens, or comparator agents mentioned in the title."", ""4. Classified 'Hematopoietic Cell' as a Primary drug-related therapy because it is the therapeutic modality being used for treatment."", ""5. Left Secondary Drugs and Comparator Drugs empty and formatted the final JSON output.""]",True,1
1023,,Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry,,[],[],[],"[""1. Read the abstract title to identify any drug names, regimens, vaccines, cell therapies, or therapeutic compounds."", ""2. Detected only disease- and genetics-related terms such as 'Chromosomal 1 Abnormalities', 'High-Risk Multiple Myeloma', and registry names, with no specific therapeutic agents mentioned."", ""3. Verified that no broad therapy terms (e.g., chemotherapy, immunotherapy) were present that might hide specific drugs."", ""4. Concluded that there are no drugs or therapeutic regimens to extract, so all output drug lists are empty.""]",True,1
1043,,Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR),,[],[],[],"[""1. Parsed the title to identify any explicit drug names or clearly defined regimens."", ""2. Detected only general phrases such as 'First Line Treatments' and a reference to 'Maia', which is a trial name rather than a drug."", ""3. No specific drug names, vaccine names, cell therapies, or standardized regimens (like FOLFOX, CHOP) were mentioned."", ""4. Per exclusion rules, broad therapy terms without specific drugs are not captured."", ""5. Concluded that there are no identifiable therapeutic drug names to classify, so all output arrays are empty.""]",True,1
1061,,Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study,,[],[],[],"[""1. Read the abstract title and identified it as an observational, retrospective registry-based study on health resource utilization in warm autoimmune hemolytic anemia."", ""2. Scanned the title for specific drug names, cell therapies, vaccines, or therapeutic regimens; none were mentioned."", ""3. Confirmed that general disease terms and study descriptors (e.g., health resource utilization, registry-based study) do not qualify as drugs per exclusion rules."", ""4. Concluded that no therapeutic agents are specified, so all drug category lists remain empty.""]",True,1
1098,,Complementary and Alternative Medicine (CAM) Use Reported Among Individuals with Immune Thrombocytopenia (ITP): Data from the ITP Natural History Study Registry,,[],[],[],"[""1. Read the abstract title and identified potential therapy-related terms."", ""2. Detected 'Complementary and Alternative Medicine (CAM)' as a broad therapy category without specific drug or agent names."", ""3. Applied exclusion rules that remove broad therapy-class terms when no specific drugs are named."", ""4. Confirmed no explicit drugs, regimens, cell therapies, or vaccines are mentioned in the title."", ""5. Returned empty arrays for all drug categories because no qualifying therapeutic agents are specified.""]",True,1
1123,,Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas,,[],[],[],"[""1. Read the abstract title to identify any terms that could represent drugs, regimens, vaccines, or cell therapies."", ""2. Detected only study/registry naming terms such as 'Clonal Hematopoiesis', 'Inflammation', 'Vasculature', 'Registry', and 'Biorepository', which are not drug names or therapeutic agents."", ""3. Confirmed there are no specific drugs, regimens, diagnostic agents used therapeutically, or cell/vaccine therapies mentioned."", ""4. Applied exclusion rules to avoid treating disease mechanisms or study infrastructure terms as drugs."", ""5. Concluded that no qualifying therapeutic or comparator drugs are present and returned empty arrays for all categories.""]",True,1
1171,,Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial,,[],[],[],"[""1. Read the abstract title to identify any explicit drug names or therapeutic regimens."", ""2. Detected only methodological/assessment terms: 'Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)' and 'Dose Review in a Phase I Clinical Trial'."", ""3. Confirmed that no specific drugs, regimens, cell therapies, or vaccines are mentioned in the title."", ""4. Applied exclusion rules to avoid treating trial phase, dose review, or PRO-CTCAE as drugs."", ""5. Concluded that there are no extractable therapeutic agents; returned empty arrays for all categories.""]",True,1
1290,,Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis,,[],[],[],"[""1. Read the abstract title and searched for specific drug names, regimens, vaccines, or cell therapies."", ""2. Detected only general terms such as 'Treatment' and 'Treatment Patterns' without any named pharmacologic agents."", ""3. Applied exclusion rules to omit broad, non-specific therapy terms (no chemotherapy, immunotherapy, or specific drug names given)."", ""4. Concluded that no identifiable therapeutic drugs or regimens are present in the title."", ""5. Returned empty arrays for all drug categories.""]",True,1
